Oct 18, 2019

The underwriting of the RE debt deals is suboptimal.  There are cases of RE debt that are clearly fraud.  Yieldstreet does not provide accurate information about the deals.  Avoid RE offerings in this platform.

Dec 26, 2017

I’m in 2 investments. One investment has been in default for several months.  Another is a litigation financing which is cash flowing poorly- well below projections. I will not be making any futures investments with YS.

Nov 08, 2017

Agreeing with Eric below. By far my favorite too.  I am in a few of the litigation portfolios yielding 12-15%. Seems the money chasing the deals is decreasing the yields.  Also in a few of their RE deals.  I feel like they do a wonderful job of due diligence and have a level of comfort that I don't have with Peer Street, POL & RealtyShares. It feels like you are working with a firm that cares about the deals and their reputation. 

I was most impressed with them when I first tried to get on their platform.  They would not let me on until they received a financial statement and credit check.  They are the only platform that has required that. 

Aug 29, 2017

By far my favorite crowdfunding platform because the uniqueness of the asset class.  Litigation finance is not correlated to the economy, the S&P 500, etc. and that at the end of the day, is what makes it an attractive addition to my portfolio.  I'm involved in more than 20 offerings (since about October 2016) and so far so good.  I did web searches, etc. like others but the two factors that convinced me to invest were: 1) Michael Weisz's talk w/the students at the Liebowitz Entrepreneur Program (you can watch on Youtube: https://youtu.be/alEVTF-wnto) 2) Their page on the deals that they did NOT do: https://www.yieldstreet.com/anti-investments 

1) Michael Weisz is extremely bright and savvy, and smart people always figure it out

2) It's quite unique for a platform who would put up a page on deals that did not make it, which shows some good introspection on their part

All in all, quite satisfied with the asset class and the platform.  The only comment I would make is that I hope in the future they will feature more offerings that are not from LawCash and also feature some commercial litigation offerings (most of the offerings currently are personal injury related)

Can't change the ratings (I'm using a Chrome browser) from the default 3.5 stars for some reason, but the ratings I would give are:

Diligence: 5

Platform fees: 3.5

Quality of Deals: 5

Jul 08, 2017

I like Yieldstreet mostly for its litigation assets, which have been returning 12-13% consistently every year. I've invested in 18 litigation offerings to date, and all are performing as expected and on time.

A typical portfolio comprises of 300-400 cases, where the minimum investment is $5-10k. This allows you to diversify across a large number of outcomes, which reduces the volatility of your returns. The case types are usually motor vehicle accidents, or slip & falls, where the judgements are already well hashed out, and thus the probability of settlement and their amounts can be modeled with some degree of accuracy (versus more complex cases, like commercial litigation, which need to be looked at case-by-case).

Portfolios are typically underwritten so that the total advance amount represents < 10% of the expected net case value, and no single lawsuit represents 5-8% of the total portfolio. Furthermore, only 10% of cases go to trial, with most settling out of court.

Before I started investing in litigation funding, I read "Investing in Justice" by Max Volsky, which I highly recommend if you're looking to understand this asset class better. 

The biggest negative is that YieldStreet doesn't provide due diligence materials for the individual cases in their portfolios. They only give you the general overview and statistics, so you have to trust either LawCash (the originator) or YieldStreet to do the proper underwriting for each case.

Overall, I like YieldStreet's litigation assets for its consistent cash flows, lack of correlation with the public markets, low counterparty risk (the obligers are usually large insurance companies), and built in diversification (< $50 invested in each lawsuit).